Malignant Eye Neoplasm — Trials

Malignant Eye Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

446 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 83
Recruiting: 44
Ph III recruiting: 10
Growth YoY: —
Industry share: 30%
Top sponsor: IDEAYA Biosciences
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (67)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06424301	Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma	recruiting	Early Phase 1	2	Eye & ENT Hospital of Fudan UniversityOTHER	1	Jun 26, 2025	clinicaltrials
NCT06972602	High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed	recruiting	Early Phase 1	10	Eye & ENT Hospital of Fudan UniversityOTHER	1	May 15, 2025	clinicaltrials